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Abstract
OBJECTIVES: The European System for Cardiac Operative Risk Evaluation (EuroSCORE) has been established as a tool for assisting deci-
sion-making in surgical patients and as a benchmark for quality assessment. Infective endocarditis often requires surgical treatment and is
associated with high mortality. This study was undertaken to (i) validate both versions of the EuroSCORE, the older logistic EuroSCORE I
and the recently developed EuroSCORE II and to compare their performances; (ii) identify predictors other than those included in the
EuroSCORE models that might further improve their performance.
METHODS: We retrospectively studied 128 patients from a single-centre registry who underwent heart surgery for active infective endo-
carditis between January 2007 and November 2014. Binary logistic regression was used to find independent predictors of mortality and to
create a new prediction model. Discrimination and calibration of models were assessed by receiver-operating characteristic curve analysis,
calibration curves and the Hosmer–Lemeshow test.
RESULTS: The observed perioperative mortality was 16.4% (n = 21). The median EuroSCORE I and EuroSCORE II were 13.9% interquartile
range (IQ) (7.0–35.0) and 6.6% IQ (3.5–18.2), respectively. Discriminative power was numerically higher for EuroSCORE II {area under the
curve (AUC) of 0.83 [95% confidence interval (CI), 0.75–0.91]} than for EuroSCORE I [0.75 (95% CI, 0.66–0.85), P = 0.09]. The Hosmer–
Lemeshow test showed good calibration for EuroSCORE II (P = 0.08) but not for EuroSCORE I (P = 0.04). EuroSCORE I tended to over-
predict and EuroSCORE II to under-predict mortality. Among the variables known to be associated with greater infective endocarditis se-
verity, only prosthetic valve infective endocarditis remained an independent predictor of mortality [odds ratio (OR) 6.6; 95% CI, 1.1–39.5;
P = 0.04]. The new model including the EuroSCORE II variables and variables known to be associated with greater infective endocarditis se-
verity showed an AUC of 0.87 (95% CI, 0.79–0.94) and differed significantly from EuroSCORE I (P = 0.03) but not from EuroSCORE II
(P = 0.4).
CONCLUSIONS: Both EuroSCORE I and II satisfactorily stratify risk in active infective endocarditis; however, EuroSCORE II performed
better in the overall comparison. Specific endocarditis features will increase model complexity without an unequivocal improvement in
predictive ability.
Keywords: Infective endocarditis • Heart surgery • Risk stratification
INTRODUCTION
Infective endocarditis (IE) is a dynamic disease constantly chan-
ging over time from an epidemiological, microbiological, diagnos-
tic and therapeutic standpoint. However, the prognosis remains
poor, especially when surgery is required [1]. Short-term mortality
rates have been reported to range from 9% [2] in elective patients
to 25–36% for those undergoing urgent surgery [2, 3]. Thus, risk
stratification is of paramount importance not only for decision-
making, but also for patient counselling (ensuring genuine
informed consent) and comparative assessment of quality of care.
Risk stratification and prediction models derived from large popu-
lations have gained popularity and are used worldwide for this
purpose [4].
The European System for Cardiac Operative Risk Evaluation
(EuroSCORE) was developed to predict procedure-related mortal-
ity rate within the first 30 days or during the initial hospitalization
in adults undergoing heart surgery. The EuroSCORE-I (ES-I) was
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initially created in 1999 [5] as an additive model and since 2003 it
has been also available in a logistic version [6]. Only 202 (1.1%)
patients of the 19 030 included in the derivation cohort had active
IE [5]. Since then, its predictive performance (mostly concerning
calibration) has been decreasing due to the changing epidemiology
of cardiac surgery case mix and the improvement of surgical techni-
ques and of postoperative care [4, 7, 8]. To overcome these limita-
tions, an updated version, the EuroSCORE-II (ES-II), was modelled
from a contemporary surgical cohort of 22381 patients, including
497 (2.2%) with active IE [9].
Nowadays, both ES-I and ES-II are both well accepted and used
routinely in clinical practice in many countries [4, 7, 9]. However,
given the singular characteristics of patients with IE that requires
surgical management and the fact that these patients were under-
represented in the derivation cohorts of the prediction models,
firm data are still lacking on their external reliability, predictive and
discriminative ability in this setting. The present study sought to (i)
externally validate both versions of the ES and to compare their
performances; (ii) identify predictors other than those included in
the ES models that might further improve their performance.
METHODS
Study design
The study population consisted of all the 128 patients who under-
went cardiac surgery under extracorporeal circulation for active IE
(according to modified Duke criteria) [10] between January 2007
and November 2014 in a single tertiary centre. Demographic, clin-
ical, laboratorial, procedure-related information and perioperative
vital status were initially retrieved from all patients from a dedicated
institutional database. When unavailable, data were completed
with information from clinical files, telephone contact or by con-
sulting the National Social Security database, for vital status. ES-I
and the new ES-II were calculated in accordance with published
guidelines using a dedicated online calculator. As both ES models
were primarily validated for perioperative mortality prediction, the
only outcome assessed was mortality at 30 days or during the index
hospitalization. All analyses performed were retrospective.
Statistical analysis
Data analysis. Normality was tested with the Kolmogorov–
Smirnov test and/or Q-Q Plot visual assessment. Continuous
variables with normal distribution were expressed as means and
standard deviation and those without normal distribution as
median and interquartile range. Discrete variables were expressed
as frequencies and percentages. Statistical comparison of baseline
characteristics was performed using Fisher’s exact test for categorical
variables, and Student’s t-test or the Mann–Whitney U-test for
continuous variables, when appropriate. Logistic regression was
used to identify independent predictors of mortality among
variables known to be associated with greater severity of IE that
were not included in the ES models.
Model performance. The relative performance of the different ES
models was compared using three different statistical methods: (i)
discriminative power, using receiver-operating characteristic (ROC)
curve analysis; (ii) calibration, using calibration curves of predicted
versus observed mortality and the Hosmer–Lemeshow goodness-
of-fit test and (iii) accuracy, using the Brier score of model residuals.
Discrimination indicates the extent to which the model distin-
guishes between patients who will die or survive in the periopera-
tive period. It was evaluated by constructing ROC curves for each
model and calculating the area under the curve (AUC) with 95%
confidence intervals (CIs). The comparison between curves was
assessed with the method described by Delong et al. [11].
Calibration refers to the agreement between observed outcomes
and predictions and was evaluated by using calibration curves and
the Hosmer–Lemeshow goodness-of-fit test. Calibration curves
were constructed by plotting predictions in the X-axis and the
observed outcome in the Y-axis (by each decile of the score-
derived predictions). Subsequently, a linear regression was applied
to the plot and a trend line was inferred. The resulting plots allow
for a visual comparison between the predicted and the observed
probability of the outcome and are characterized by an intercept,
which indicates the extent to which predictions are systematically
low or high, and a calibration slope that should be 0. The perfectly
calibrated predictions stay on the 45° line, whereas a curve
below or above the diagonal reflects over- and under-prediction,
respectively. Furthermore, calibration was tested with the Hosmer–
Lemeshow goodness-of-fit test, which compares observed with
predicted values by decile of predicted probability.
The accuracy of the models was also tested calculating the Brier
score [the quadratic difference between predicted probability and
observed binary outcome (0 for no event and 1 for event) for each
patient]. It is an overall performance measure that ranges between
0 and 1 with lower values indicating better performance.
All tests were two-sided and differences were considered statistic-
ally significant at a P-value of 0.05. Statistical analysis was performed
with the SPSS 20.0 software (SPSS, Inc., Chicago, IL, USA) and
MedCalc version 9.3.8.0 (MedCalc ©, Acacialaan Ostend, Belgium).
RESULTS
Population and surgery features
During the study time frame, 128 patients were submitted to
heart surgery due to active IE. Ninety-six patients (75%) were
male and the median age was 60 interquartile range (IQ) (47–70)
years. Almost 80% of the patients had some kind of renal impair-
ment including 14 patients (11%) on dialysis before surgery; 22%
(n = 28) had left ventricular systolic dysfunction; 60% (n = 62)
were in NYHA functional class III or IV at the time of surgery.
Demographic and clinical baseline characteristics are summarized
in Tables 1 and 2, for variables included and not included in the
EuroSCOREs, respectively.
Surgery was considered urgent in 92% (n = 117) of the cases,
emergent in 6% (n = 8) and salvage in 2% (n = 3). The main reasons
for surgery were refractory heart failure due to valvular dysfunc-
tion and persistent infection. The description of the interventions
is given in Table 3.
Specific endocarditis-related features (type of endocarditis,
affected valves and causal agent) are described in Table 4.
Mortality
Observed mortality was 16% (n = 21), the median (IQ) time from
surgery until the fatal event was 4 (1.75–30) days and 78% of
deaths occurred within 30 days.
Patients who died within 30 days after surgery or during the
index hospital admission were significantly older [65 IQ (57–74) vs
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58 IQ (45–69) years old; P = 0.02], presented more frequently with
perivalvular complications (48 vs 24%; P = 0.04), critical periopera-
tive state (24 vs 8%; P = 0.05), creatinine clearance <85 ml/min
(95 vs 75%; P = 0.04) and with higher levels of white blood cell
count (>12.4 × 109/l, cut-off determined by c-statistics), had a
higher prevalence of underlying heart disease (67 vs 39%;
Table 2: Baseline and laboratory characteristics not included in the ES models
Total (n = 128) Alive (n = 107) Perioperative mortality (n = 21) P-value*
Patient-related factors
Body mass index (kg/m2) 25 ± 5.2 25 ± 5.2 26 ± 5.3 0.28
Underlying heart disease 56 (43.8%) 42 (39.3%) 14 (66.7%) 0.03
Laboratory
Haemoglobin (g/dl) 9.7 (8.8–10.6) 9.7 (8.9–10.6) 9.6 (8.5–10.2) 0.54
White blood cell 8450 (6675–13 425) 8200 (6600–12 600) 12 500 (7050–14 650) 0.11
C-reactive protein (mg/dl) 5.3 (2.2–12.6) 5.2 (2–10) 7 (3.4–16.9) 0.11
Platelets 238 (158–308) 234 (157–302) 262 (159–345) 0.26
Haemoglobin <10a g/dl 75 (58.6%) 60 (56%) 15 (71.4%) 0.23
White blood cell >12 400a 40 (31.3%) 29 (27%) 11 (52.4%) 0.04
C-reactive protein >3a mg/dl 89 (69.5%) 71 (66.4%) 18 (85.7%) 0.12
Platelets <297a 42 (33%) 32 (30%) 10 (47.6%) 0.13
aBest discriminative value for operative mortality by ROC curve analysis.
*P-values are for the comparison between patients who died during the index admission or at 30 days versus those who survived.
Table 1: Baseline characteristics included in the ES models
Total (n = 128) Alive (n = 107) Perioperative mortality (n = 21) P-value*
Patient-related factors
Age (years) 60 IQ (47–70) 58 IQ (45–69) 65 IQ (57–74) 0.02
Male sex 96 (75%) 82 (77%) 14 (67%) 0.41
Extracardiac arteriopathy 10 (7.8%) 7 (6.5%) 3 (14.3%) 0.21
Poor mobility 12 (9.4%) 11 (10.3%) 1 (4.8%) 0.69
Previous cardiac surgery 30 (23.4%) 17 (15.9%) 13 (62%) <0.001
Renal function
Creatinine clearance >85 ml/min 26 (20%) 25 (23.4%) 1 (4.8%) 0.07
Creatinine clearance 50–85 ml/min 42 (33%) 37 (35%) 5 (32.8%) 0.45
Creatinine clearance <50 ml/min 46 (36%) 34 (32%) 12 (57%) 0.04
Serum creatinine >200 mmol/l 37 (28.9%) 29 (27%) 8 (38%) 0.3
Dialysis 14 (11%) 11 (10%) 3 (14.3%) 0.7
Chronic lung disease 10 (7.8%) 9 (8.4%) 1 (4.8%) 0.35
Critical preoperative state 14 (11%) 9 (8.4%) 5 (24%) 0.05
Diabetes 21 (16.4%) 15 (14%) 6 (28.6%) 0.11
Diabetes on insulin 6 (4.7%) 4 (3.7%) 2 (9.5%) 0.25
Cerebrovascular disease 4 (3.1%) 3 (2.8%) 1 (4.8%) 1
LV ejection fraction
Good (LVEF >50%) 100 (78%) 86 (80.4%) 14 (66.7%) 0.25
Moderate (LVEF 31–50%) 22 (17.2%) 17 (15.9%) 5 (23.8%) 0.36
Poor (LVEF 21–30%) 6 (4.7%) 4 (3.7%) 2 (9.5%) 0.26
Very poor (LVEF <20%) 0 0 0 NA
CCS class 4 angina 2 (1.6%) 1 (0.9%) 1 (4.8%) 0.3
Recent MI <90 days 3 (2.3%) 1 (0.9%) 2 (9.5%) 0.07
NYHA
NYHA IV 38 (29.7%) 32 (30%) 6 (28.6%) 1.0
NYHA III 39 (30.5%) 30 (28%) 6 (28.6%) 0.2
NYHA II 26 (20.3%) 23 (21.5%) 3 (14.3%) 0.56
NYHA I 25 (19.5%) 22 (20.6%) 3 (14.3%) 0.76
Pulmonary hypertension
Moderate (PASP 31–55 mmHg) 9 (7%) 7 (6.5%) 2 (9.5%) 0.64
Severe (PASP >55 mmHg) 15 (11.7%) 13 (12.1%) 2 (16.7%) 1.0
EuroSCORE I (%) 24.4 ± 22.8 21.3 ± 20.6 40.1 ± 27.1 <0.001
EuroSCORE II (%) 11.9 ± 12.9 9.3 ± 9.7 25.2 ± 18.6 <0.001
*P-values are for the comparison between patients who died during the index admission or at 30 days versus those who survived.
ES: EuroSCORE; EuroSCORE: European System for Cardiac Operative Risk Evaluation; IQ: interquartile range; CCS: Canadian Cardiovascular Society grading
system for stable angina; LVEF: left ventricle ejection fraction; MI: myocardial infarction; NYHA: New York Heart Association functional class; PASP: pulmonary
artery systolic pressure.
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P = 0.03), prior heart surgery (62 vs 16%; P < 0.001), prosthetic
(versus native valve) endocarditis (62 vs 15.0%; P < 0.001) and
underwent salvage surgery more frequently (14 vs 0.0%;
P = 0.004). Of these, only the type of endocarditis (prosthetic
versus native), perivalvular complications, underlying heart
disease and white blood cell count are not included in the ES
scoring systems. These variables were analysed in a multivariable
regression including the ES-I and ES-II models, separately. In the
analysis performed with ES-II, only this model and prosthetic
valve IE proved to be independent predictors of mortality [odds
ratio (OR) 1.06; 95% CI, 1.01–1.105; P = 0.01 and OR 6.6; 95% CI,
1.1–39.5; P = 0.04, respectively]. In the model including ES-I, only
prosthetic valve IE preserved predictive ability (OR 7.6; 95% CI,
1.3–43; P = 0.02).
Performance of the EuroSCORE logistic models
Discriminative power. The mean values of the ES-I and II were
24.4 ± 22.8 and 11.9 ± 12.9, respectively (Table 1). The area under
the ROC curve for the ES-I was 0.75 (95% CI, 0.66–0.85) and 0.83
(95% CI, 0.75–0.91) for the ES-II. Despite being numerically
superior for the ES-II, the difference was not statistically significant
(DeLong test, P = 0.094) (Table 5). The ‘new’ model including the
ES-II variables and variables known to be associated with greater
IE severity (modified ES-II) showed an AUC of 0.87 (95% CI, 0.79–
0.94), and differed significantly from ES-I (DeLong test, P = 0.03)
but not from ES-II (DeLong test, P = 0.4).
The ROC curves for all the models with respect to the study
end-point are depicted in Fig. 1.
Table 4: Endocarditis-related features
Total (n = 128) Alive (n = 107) Perioperative mortality (n = 21) P-value*
Type of endocarditis
Native valve 94 (73.4%) 81 (75.7%) 7 (33.3%) <0.001
Prosthetic 29 (22.7%) 16 (15%) 13 (62%) <0.001
Intracardiac device 5 (3.9%) 5 (4.6%) 0 (0%) 1
Involved structures
Aortic valve 64 (50%) 57 (53.3%) 7 (33.3%) 0.15
Mitral valve 66 (51.6%) 52 (48.6%) 14 (66.7%) 0.15
Tricuspid valve 10 (7.8%) 8 (7.5%) 2 (9.5%) 0.67
Multivalvular 20 (15.6%) 16 (15%) 4 (19%) 0.74
Causal agents
Streptococcus species 24 (19%) 23 (21.7%) 1 (4.8%) 0.12
Staphylococcus species 24 (18.8%) 18 (16.8%) 6 (28.6%) 0.23
Enterococcus 15 (11.7%) 14 (13.1%) 1 (4.8%) 0.46
Gram-negative bacteria 15 (11.7%) 12 (11.2%) 3 (14.3%) 0.71
Fungus 5 (3.9%) 4 (3.7%) 1 (4.8%) 1
Not identified 42 (32.8%) 32 (29.9%) 10 (47.6%) 0.13
*P-values are for the comparison between patients who died during the index admission or at 30 days versus those who survived.
Table 3: Surgical features
Total (n = 128) Alive (n = 107) Perioperative mortality (n = 21) P-value*
Reason for surgery
Refractory heart failure due to valvular dysfunction 95 (74.2%) 81 (75.7%) 14 (66.7%) 0.42
Persistent infection 64 (50%) 52 (48.6%) 12 (57.1%) 0.63
Recurrent embolism 21 (16.4%) 18 (16.8%) 3 (14.3%) 1
Perivalvular complications 56 (28.1%) 26 (24.3%) 10 (47.6%) 0.04
Urgency
Elective 0 0 0 NA
Urgent 117 (91.4%) 101 (94.4%) 16 (76.7%) 0.02
Emergent 8 (6.3%) 6 (5.6%) 2 (9.5%) 0.62
Salvage 3 (2.3%) 0 3 (14.3%) 0.004
Weight of the intervention
Isolated CABG 0 0 0 NA
Single non-CABG 104 (81.3%) 86 (80.4%) 18 (85.7%) 0.76
Two procedures 23 (18%) 21 (19.6%) 2 (9.5%) 0.36
Three procedures 1 (0.8%) 0 1 (4.8%) 0.16
Surgery on thoracic aorta 4 (3.1%) 4 (3.7%) 0 1.0
Duration of hospital admission in our institution (days) 22 (9–44) 22 (9–63) 11 (2–43) 0.07
*P-values are for the comparison between patients who died during the index admission or at 30 days versus those who survived.
CABG: coronary artery by-pass grafting; NA: not applicable.
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Calibration and accuracy. The calibration curves of ES I, ES-II
and modified ES-II are shown in Fig. 2 The pattern of calibration
was different between the scores: the ES-I showed a progressive
trend towards over-prediction; on the other hand, ES-II and
modified ES-II tended to under-predict mortality.
The calibration curve slope and intercept for each model is
summarized in Table 5. ES-II and modified ES-II had non-
significant P-values (P = 0.08 for ES-II and P = 0.28 for modified
ES-II) for the Hosmer–Lemeshow test indicating that they would
provide accurate probabilities whereas ES-I showed poor calibra-
tion (P = 0.04) (Table 5). The overall performance ascertained by
the Brier score was good, with values near to 0 (Table 5).
DISCUSSION
This single-centre study, based on consecutive patients who
underwent cardiac surgery for active IE, demonstrates that both
Table 5: Predictive performance-related statistics
EuroSCORE I EuroSCORE II Modified
EuroSCORE II
Overall performance
Brier score 0.13 0.11 0.10
Discrimination
AUC (95% CI) 0.75
(0.66–0.85)
0.83
(0.75–0.91)
0.87
(0.79–0.94)
Calibration
Slope 0.49 1.1 0.8
Intercept 4.2 2.9 1.9
Hosmer–Lemeshow
test, P-value
0.04 0.08 0.287
R2 Nagelkerke 0.136 0.263 0.318
χ2 15.9 13.9 9.7
AUC: area under the curve; CI: confidence interval.
Figure 1: ROC curves for EuroSCORE I, EuroSCORE II and modified EuroSCORE
II. EuroSCORE: European System for Cardiac Operative Risk Evaluation.
Figure 2: Calibration curves of the EuroSCORE I (A), EuroSCORE II (B) and
modified EuroSCORE II (C) predictions. EuroSCORE: European System for
Cardiac Operative Risk Evaluation.
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ES-I and ES-II adequately stratify the risk of operative mortality;
however, ES-II is better fitted to the current case mix. Also, we
found that adding specific IE features to the model would not sig-
nificantly improve the performance of ES-II, under penalty of in-
creasing model complexity.
It is well known that risk assessment is central in the evaluation
of the perioperative risk. The application of risk stratification tools
gives an objective appraisal of risk for both physicians and
patients. However, some features may not be fully covered by the
models, namely (i) centre-to-centre variability in outcomes, (ii)
type of surgery required and (iii) inherent complexity of some dis-
eases, in this case IE.
The ES-II and ES-I were conceived from a broad case mix,
including few patients with active infective endocarditis and their
contribution might have been diluted in the final model. The per-
formance of these scoring systems is unknown in this specific
population.
Since its release, the prognostic value of the ES-1 has been ex-
tensively proven and its use is recommended as a risk stratification
score in both European myocardial revascularization and valvular
heart disease guidelines [12, 13]. It was modelled from a surgical
population of 1995, wherein most of the procedures were isolated
coronary artery bypass grafting (CABG) surgery and only 30% were
valvular [5], which is reflected in poorer performance of the model
in the later subset of patients [8]. With the improved surgical out-
comes and changing demography, the ES-I lost its discrimination
and specially calibration power for the nowadays-surgical popula-
tion [4, 7–9]. The ES-II was conceived to overcome these limita-
tions. It was derived from a population of patients operated in
2010, in which valvular and isolated CABG procedures were well
balanced [9]. It showed a very good discriminative ability in both
internal and external European validation cohorts (AUC varying
between 0.809 and 0.856) [4, 14, 15] and fair discrimination in a
Chinese cohort (AUC of 0.72) [16] in overall surgical populations.
Several studies demonstrated better discrimination for non-CABG
procedures [14–16] though one study revealed an optimal per-
formance in a sub-population of isolated CABG [17]. ES-II per-
formance was lower than expected among patients undergoing
emergency/salvage surgery and combined procedures in one
study [18]. Despite the improved discrimination, calibration
remained unsatisfactory [4, 9, 14–16]. The internal validation study
and most of the external validation studies showed a trend toward
under-prediction of mortality [9, 14–16, 19], still the ES-II showed
optimal calibration until 30% of the predicted risk followed by a
progressive over-prediction in high-risk patients in the largest
external validation cohort performed by Barili et al. [4].
Since the ES-II release in 2011, several comparisons between
the updated ES-II and the logarithmic version of the original ES
have been made in multiple surgical settings and populations [4,
15, 16, 18–23]. The results are conflicting. The majority of these
studies showed an improved performance of the updated version
regarding both discrimination and calibration for CABG and
non-CABG procedures [15, 16, 18, 23]. However, other reports
showed the opposite, being two of these studies from non-European
cohorts [19–22]. In the largest comparison ever performed, the ES-II
did not seem to significantly improve the performance of the older
version in the higher tertiles of risk [4]. Despite these differences, the
ES-II performed well (AUC >0.8) in a significant portion of these
studies [15, 18, 21, 22].
Table 6 summarizes the main characteristics and results of the
aforementioned studies.
In our cohort, the discriminative power of ES-I was less than
optimal whereas ES-II showed good discrimination. The AUC of
ES-I for perioperative mortality was 0.75, similar to that shown in
other nowadays-overall surgical cohorts (AUCs for ES-I between
0.67 and 0.82) [4, 15, 16, 18, 19, 21, 23]. Mestres et al. [24] had
already validated the ES-I in a registry that included patients with
active and past endocarditis; in this study, ES-I showed good cali-
bration and discrimination for the entire cohort and for specific
surgical subsets. The ES-II discriminated well with an AUC of 0.83,
similar to previous reports from overall surgical cohorts (AUCs for
ES-II between 0.72 and 0.84) [4, 14–16, 18, 19, 21–23].
Our study cohort comprises a high-risk subset of patients,
which is reflected by the high values of both ES models. In patients
within this range of risk, it is expected that the ES-I over-predicts
risk [4, 19, 20, 23]; however, such anticipation is not possible for
ES-II since its behaviour across the risk spectrum remains contro-
versial [4, 9, 14–16, 19]. Calibration curves were constructed to
assess the behaviour of both ES models across the risk spectrum.
The ES-I showed poor calibration (Hosmer–Lemeshow test,
Table 6: EuroSCORE I versus EuroSCORE II comparison studies
Discrimination
(AUC)
Calibration
Study n Population ES-I ES-II ES-I ES-II
Arnaiz-Garcia et al. [20] (Spain) 1200 Mixed − − Over-predicted Under-predicted
Barili et al. [4] (Italy) 12 325 Mixed 0.82 0.82 Over-predicted Optimal until 30%-predicted
mortality than over-predicts
Chalmers et al. [15] (UK) 2913 Mixed 0.74 0.82 − −
Koszta et al. [18] (Hungary) 2287 Mixed 0.80 0.82 − −
Lisboa et al. [21] (Brazil) 1000 Mixed 0.81 0.81 HLT, P = 0.59 HLT, P < 0.05
Nishida et al. [23] ( Japan) 461 Thoracic aortic surgery 0.72 0.77 Over-predicted Near optimal
Qadir et al. [22] (Pakistan) 2004 Isolated CABG − 0.84 HLT, P = 0.23 HLT, P < 0.05
Velicki et al. [19] (Serbia) 1247 Mixed 0.76 0.74 Over-predicted Under-predicted
Wang et al. [16] (China) 11 170 Valvular 0.67 0.72 HLT, P < 0.05 HLT, P < 0.05
AUC: area under the curve; AVR: aortic valve replacement; CABG: coronary artery by-pass grafting; ES: EuroSCORE; HLT: Hosmer–Lemeshow test (P < 0.05
indicates poor calibration).
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P = 0.04) and over-predicted mortality. On the other hand, ES-II
showed appropriate calibration (Hosmer–Lemeshow test, P = 0.08)
and a trend to under-prediction. ES-I behaved differently for
low-risk and intermediate/high-risk patients. The ES-I showed an
initially under-prediction until 8% of predicted mortality, then
intersected the optimal prediction line and exhibited a progres-
sive over-prediction, more pronounced in patients at higher risk.
This kind of performance can lead to an unrealistic optimism in
patients with less risk and at a preposterous concern in those at
highest risk. On the other hand, ES-II showed a progressive under-
prediction throughout all risk spectra. Despite these trends for
over-prediction in ES-I and under-prediction in ES-II, it appears
that both scores are better suited for patients at low risk, which is
in consonance with the published literature [4, 8, 9].
For clinical purposes, the ES-II seems to have a more predict-
able and better behaviour for estimating risk. Overall ES-II per-
formed better than ES-I in predicting perioperative mortality. This
was a predictable result, since the ES-II was derived from a popu-
lation that reflects contemporary surgical practice and demog-
raphy of most European countries [9], and because the ES-I has
worse performance in valvular patients [8].
Several variables not included in the ES models (prosthetic
valve IE, perivalvular complications, underlying heart disease and
white blood cell count) were associated with perioperative mor-
tality. Only prosthetic valve endocarditis was shown to be a strong
independent predictor of mortality (as demonstrated in other
series) [1] regardless of ES models. Furthermore, when tested with
both ES models separately, ES-I lost its predictive ability. For this
reason, we constructed a model including the variables associated
with greater IE severity and the ES-II (modified ES-II). The overall
performance of the modified ES-II was the best among the three
models regarding discrimination and calibration, however did not
differ significantly from the ES-II.
In summary, our data suggest that the performance of the ES-I
and ES-II in estimating perioperative risk in patients undergoing
heart surgery for infective endocarditis is comparable with that of
other current overall surgical cohorts, supporting the general
trend towards better performance of the ES-II. The greatest ad-
vantage of ES-II is its more predictable behaviour across the risk
spectrum, allowing more accurate risk estimation. This is of para-
mount importance for patient and family counselling as well as for
surgeon’s management of expectations and care. The current
model of ES-II is quite comprehensive and additional infective
endocarditis features did not increase its performance, reinforcing
the evidence that the ES-II is an across-the-board tool for risk esti-
mation in current surgical practice.
Limitations
The inherent limitations of a retrospective analysis are: (i) the sub-
jectivity of those who collect the data and make records (ii) con-
finement to the data prospectively collected, not allowing other
important data to be included. The fact that poor mobility was not
discriminated at the time that data were collected implied the as-
sumption that previous serious neurological dysfunction and
morbid obesity were surrogates, as well as the description of de-
pendency in the surgeon notes. As all single-centre studies, the
external validity is potentially limited. This is particularly important
in this setting since microbiological profile, surgical and post-
procedural care vary widely between centres. The small sample
size (however, it accounts for almost half and one-fifth of the cases
included in the ES-I and ES-II development studies, respectively)
may have limited the power of the statistical analysis (due to Type
II error) and the ability to find statistical significance for many of
the comparisons. However, our results are solid and in line with
previous evidence on the comparative performance of ES predict-
ive models, and may contribute to further understanding of ES
models in this specific surgical subset of patients. Finally, the fact
that 55% of the included patients came from secondary centres
without cardiac surgery (i) makes it extremely difficult to make
assumptions about the time from presentation to diagnosis and
from diagnosis to surgery. The later fact may explain why so many
patients presented with more than one indication for surgery, sug-
gesting delay in referral (IE is frequently misdiagnosed at presenta-
tion and initial management in secondary centres is usually
performed by doctors less familiarized with natural history and
surgical indications); (ii) may have contributed to a selection bias,
with the invoice of patients with more severe and advanced
disease but on average younger, with a lower number of co-
morbidities and at overall lower surgical risk in comparison with
the whole population of patients suffering from endocarditis.
CONCLUSIONS
Our analysis of patients with active IE undergoing heart surgery
indicates a better overall predictive performance of the
EuroSCORE II over the logarithmic EuroSCORE. Specific endocar-
ditis features will increase model complexity without an un-
equivocal improvement in predictive ability. The present findings
indicate that the EuroSCORE II may be a useful and appropriate
tool for estimating perioperative risk in a nowadays-active infect-
ive endocarditis population. Larger and prospective studies are
warranted for further validation.
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